Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19078876 | 0.80 | — | — | |
| SCHEMBL17280944 | 0.79 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL16301663 | 0.77 | HTT (0.34) | HTTKDM5BMAPK1SMN1; SMN2 | |
| SCHEMBL3062268 | 0.77 | HTT (0.31) | HTT | |
| SCHEMBL12755617 | 0.76 | HTT (0.36) | HTTKDM5BGAA | |
| SCHEMBL2323075 | 0.76 | — | — | |
| SCHEMBL16414383 | 0.76 | IDO1 (0.30) | — | |
| SCHEMBL15470592 | 0.76 | KDM4E (0.37) | — | |
| SCHEMBL8020079 | 0.76 | MAPK1 (0.34) | HTTGAAMAPK1SMN1; SMN2 | |
| SCHEMBL10393962 | 0.76 | MAPK1 (0.34) | HTTGAAMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9556158-B2 | Fungicidal 3-[(pyridin-2-ylmethoxyimino)(phenyl)methyl]-2-substituted-1,2,4-oxadiazol-5(2H)-one derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-2604633-B1 | MANUFACTURING METHOD OF (METH) ACRYLIC POLYMER | KANEKA CORP (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140350058-A1 | FUNGICIDAL 3-[(PYRIDIN-2-YLMETHOXYIMINO)(PHENYL)METHYL]-2-SUBSTITUTED-1,2,4-OXADIAZOL-5(2H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8822318-B2 | Doping of semiconductor substrate through carbonless phosphorous-containing layer | INERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130295754-A1 | DOPING OF SEMICONDUCTOR SUBSTRATE THROUGH CARBONLESS PHOSPHOROUS-CONTAINING LAYER | GLOBALFOUNDRIES U.S. INC. | 2013-11-07 | — | — | US | disclosed |
| US-8481413-B2 | Doping of semiconductor substrate through carbonless phosphorous-containing layer | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110223751-A1 | DOPING OF SEMICONDUCTOR SUBSTRATE THROUGH CARBONLESS PHOSPHOROUS-CONTAINING LAYER | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-7166553-B2 | Mixed catalyst compositions for the production of polyolefins | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-4006149-A | COBALT CONTAINING | STUDIENGESELLSCHAFT KOHLE M.B.H. (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 755/4885KDM5B 2119/4885GAA 13/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885KDM5B 1569/4885GAA 14/4885 |
| US-20140350058-A1 | FUNGICIDAL 3-[(PYRIDIN-2-YLMETHOXYIMINO)(PHENYL)METHYL]-2-SUBSTITUTED-1,2,4-OXADIAZOL-5(2H)-ONE DERIVATIVES | CYP51A1, AZI2, PNPO | HTT 4352/4885KDM5B 48/4885GAA 1357/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885KDM5B 1569/4885GAA 14/4885 |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | ALDOA, IDE, ACAT1 | HTT 428/4885KDM5B 2049/4885GAA 15/4885 |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885KDM5B 1569/4885GAA 14/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | HTT 577/4885KDM5B 1043/4885GAA 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.